166 related articles for article (PubMed ID: 17943227)
1. Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.
Durocher F; Labrie Y; Ouellette G; ; Simard J
J Hum Genet; 2007; 52(12):963-977. PubMed ID: 17943227
[TBL] [Abstract][Full Text] [Related]
2. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
3. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Durocher F;
J Hum Genet; 2009 Mar; 54(3):152-61. PubMed ID: 19197335
[TBL] [Abstract][Full Text] [Related]
4. Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer.
Desjardins S; Ouellette G; Labrie Y; Simard J; ; Durocher F
J Hum Genet; 2008; 53(6):490-498. PubMed ID: 18350249
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families.
Desjardins S; Belleau P; Labrie Y; Ouellette G; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; ; Durocher F
Int J Cancer; 2008 Jan; 122(1):108-16. PubMed ID: 17764113
[TBL] [Abstract][Full Text] [Related]
6. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.
Lockett KL; Hall MC; Xu J; Zheng SL; Berwick M; Chuang SC; Clark PE; Cramer SD; Lohman K; Hu JJ
Cancer Res; 2004 Sep; 64(17):6344-8. PubMed ID: 15342424
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Pichette R; Plante M; Durocher F;
Fam Cancer; 2007; 6(4):483-90. PubMed ID: 17636424
[TBL] [Abstract][Full Text] [Related]
8. Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
Plourde M; Samson C; Durocher F; Sinilnokova O; Simard J;
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):115-28. PubMed ID: 18083510
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
[TBL] [Abstract][Full Text] [Related]
10. Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Desjardins S; Beauparlant JC; Labrie Y; Ouellette G; Durocher F;
BMC Cancer; 2009 Jun; 9():181. PubMed ID: 19523210
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
12. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.
Plourde KV; Labrie Y; Desjardins S; Belleau P; Ouellette G; Durocher F;
J Hum Genet; 2013 Feb; 58(2):59-66. PubMed ID: 23151675
[TBL] [Abstract][Full Text] [Related]
14. Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Cao WH; Wang X; Frappart L; Rigal D; Wang ZQ; Shen Y; Tong WM
Mutat Res; 2007 Aug; 632(1-2):20-8. PubMed ID: 17560163
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
[TBL] [Abstract][Full Text] [Related]
16. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
17. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
Cavallone L; Arcand SL; Maugard C; Ghadirian P; Mes-Masson AM; Provencher D; Tonin PN
BMC Cancer; 2008 Apr; 8():96. PubMed ID: 18402691
[TBL] [Abstract][Full Text] [Related]
18. Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.
Plourde M; Ferland A; Soucy P; Hamdi Y; Tranchant M; Durocher F; Sinilnikova O; Luu The V; ; Simard J
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):134-53. PubMed ID: 19460435
[TBL] [Abstract][Full Text] [Related]
19. Mutation analysis of PALB2 gene in French breast cancer families.
Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
[TBL] [Abstract][Full Text] [Related]
20. Functional Evaluation of ZNF350 Missense Genetic Variants Associated with Breast Cancer Susceptibility.
Zhang N; Lu Y; Liu X; Yu D; Lv Z; Yang M
DNA Cell Biol; 2018 Jun; 37(6):543-550. PubMed ID: 29653063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
